# Annexon, Inc. (ANNX) — capital_raise/private_placement [announced]
Source: SEC API (secapi.ai) · situation sit_77b5efb7b040642d25f4 · retrieved 2026-08-12T21:28:51.688Z

## Overview
Annexon, Inc. is a biopharmaceutical company developing complement-based therapies, with product candidates Tanruprubart for Guillain-Barré Syndrome and Vonaprument for Geographic Atrophy.

Annexon, Inc. entered into a Loan and Security Agreement with Oxford Finance LLC as collateral agent on July 30, 2026, providing for term loans in an aggregate principal amount of up to $200.0 million. The initial tranche of $50.0 million was funded on the Effective Date. Three additional tranches totaling up to $100.0 million are available upon achievement of specified milestones and conditions, and one additional uncommitted tranche of up to $50.0 million is available upon mutual agreement of the parties. The term loans bear interest at a floating rate equal to the greater of (i) the 1-Month CME Term SOFR plus 4.6% and (ii) 7.60%. The loans mature on July 1, 2031, or June 1, 2032, depending on achievement of certain milestones. Borrower must make monthly interest-only payments until September 1, 2029 (extendable to September 1, 2030 or 2031 depending on milestones), after which monthly principal and interest payments are due. Annexon granted Oxford Finance a security interest in substantially all of its assets to secure the obligations.

## Terms
- Counterparty: Oxford Finance LLC · Deal value: $200.0M · Consideration: cash

## Key dates
- Announced 2026-07-30

## Timeline
- 2026-07-30 · 8-K (0001193125-26-326199): 8-K - Annexon, Inc. — *Annexon, Inc. is a biopharmaceutical company developing complement-based therapies, with product candidates Tanruprubart for Guillain-Barré Syndrome and Vonaprument for Geographic Atrophy.* Annexon, Inc. entered into a Loan and Security Agreement with Oxford Finance LLC as collateral agent on July 30, 2026, providing for term loans in an aggregate principal amount of up to $200.0 million. The initial tranche of $50.0 million was funded on the Effective Date. Three additional tranches totaling up to $100.0 million are available upon achievement of specified milestones and conditions, and one additional uncommitted tranche of up to $50.0 million is available upon mutual agreement of the parties. The term loans bear interest at a floating rate equal to the greater of (i) the 1-Month CME Term SOFR plus 4.6% and (ii) 7.60%. The loans mature on July 1, 2031, or June 1, 2032, depending on achievement of certain milestones. Borrower must make monthly interest-only payments until September 1, 2029 (extendable to September 1, 2030 or 2031 depending on milestones), after which monthly principal and interest payments are due. Annexon granted Oxford Finance a security interest in substantially all of its assets to secure the obligations.
  https://www.sec.gov/Archives/edgar/data/1528115/0001193125-26-326199.txt

## Citations
- 0001193125-26-326199 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526326199